ban on tirzepatide Compounding pharmacies can resume making as FDA reconsiders shortage Lilly's weight-loss drug removed from

PAD is a condition in which arteries become narrowed due to the buildup of fatty deposits, reducing blood flow to the limbs, most commonly the legs...

GLP-1 meds dont just curb appetitesometimes they curb essential nutrients too

Weeks 1316

Never inject a pen that may have been frozen, even if it looks normal

Liver-directed therapies with efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD), including incretin-based agents, fibroblast growth factor 21 analogs, peroxisome proliferator-activated receptor agonists, and thyroid hormone receptor beta agonists, may benefit selected MetALD patients